International Psoriasis Council

Advancing Knowledge. Improving Care.

Richard Langley Headshot

Richard

Langley

,

FRCPC, FACP

Director of Research in the Division of Clinical Dermatology and Cutaneous Science
Dalhousie University
Halifax
,
Nova Scotia
,
Canada
Councilor Since: January 1, 2006
IPC Councilor
Dr. Richard Langley is a dermatologist, Professor of Medicine, and Director of Research in the Division of Clinical Dermatology and Cutaneous Science. An internationally recognized award-winning expert on psoriasis and skin cancer, he is a widely published author and regular reviewer for several medical and dermatology journals. Dr. Langley’s research focuses on cutaneous melanoma, psoriasis, atopic dermatitis, skin cancer, and other inflammatory skin diseases. His work on melanoma involves an in vivo confocal scanning laser microscope — the first of its kind in Canada — which permits instantaneous high-resolution images at the cellular level.
Last Updated:
01/25/2018

Areas of Interest

Clinical trials, methodology, study design, and long term safety (special interest in malignancy).

Languages Spoken

English

Involvement with Other Organization(s)

Serves on the Medical Board of the National Psoriasis Foundation (NPF); provides consultation for drugs being approved for Health Canada; assisted in the package preparation for sponsors to the United States Food and Drug Administration (FDA).

What's New

First-Line Biologics in Psoriasis: Evidence from the BADBIR Cohort Study

In this IPC commentary, Matias Maskin examines evidence from the BADBIR registry demonstrating that first-line biologic therapy in moderate to severe psoriasis leads to faster skin clearance, improved quality of life, and a lower risk of comorbidities. The analysis challenges traditional step-up approaches and supports earlier, patient-centered treatment strategies.

Read More »

Recent Advances in Psoriasis: A Year in Review

In this Take Ten with IPC video, Dr. Leandro Leite discusses the most recent advances in psoriasis over the last year (March 2025 – March 2026). Topics include new guidelines, research, and recent studies.

WATCH NOW

Monday, April 6, 2026